Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Bak SP, Barnkob MS, Wittrup KD, Chen J.

Cancer Immunol Res. 2013 Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20.

2.

Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.

Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J.

J Immunol. 2012 Aug 15;189(4):1708-16. doi: 10.4049/jimmunol.1201271. Epub 2012 Jul 13.

3.

Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer.

Hart KM, Bak SP, Alonso A, Berwin B.

Neoplasia. 2009 Jun;11(6):564-73, 1 p following 573.

4.

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

Bak SP, Alonso A, Turk MJ, Berwin B.

Mol Immunol. 2008 Dec;46(2):258-68. doi: 10.1016/j.molimm.2008.08.266. Epub 2008 Sep 27.

5.

Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses.

Bak SP, Amiel E, Walters JJ, Berwin B.

Mol Immunol. 2008 Mar;45(5):1414-23. Epub 2007 Oct 23.

6.

Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.

Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR, Berwin BL.

Cancer Res. 2007 May 15;67(10):4783-9.

Supplemental Content

Support Center